Revance Therapeutics Inc (RVNC)

[DewDiligence]

Cut the price. Daxxify should be priced no more than 25% higher than Botox.

I concur (see #msg-172624444), but I think the upper bound of the range for the price premium should be 10-20% (rather than 25%).

On the 2Q23 CC, Mark Foley acknowledged that there have been some GL patients who didn’t think Daxxify’s extended duration was worth the price premium relative to Botox. Narrowing the price premium ought to get many of these patients to switch back to Daxxify and get other patients to try it for the first time.